BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

I feel for the CEGE group but even though the orphan GVAX portfolio has been sold to Aduro, they manage to spin off Cold Genesys and Ceregene which appears to be further down the development path and potentially larger revenue generators. So hopefully, these all pan out.

You have every right to be skeptical. But on the surface, the fact that the R/S also applies to outstanding shares is probably intended to send a strong signal to the markets that ANI feels confident they will be using revenues to grow the company, no more dilution to fund research or operations. Let us hope this is the case.


By contrast when Biosante did the last R/S the did not reduce their total outstanding shares according. This sent the message that further dilution will be coming. Which is exactly what happened.

Time for a good PR streak.

GLTA